Evaluation of the Birmingham IBS symptom questionnaire

Andrea K Roalfe, Lesley M Roberts, Sue Wilson, Andrea K Roalfe, Lesley M Roberts, Sue Wilson

Abstract

Background: Irritable Bowel Syndrome (IBS) is a chronic/common condition that causes a significant effect on the individual (reduced quality of life), society (time lost off work) and health services. Comparison of studies evaluating the management of IBS has been hindered by the lack of a widely adopted validated symptom score. The aim of this study was to develop and validate a disease specific score to measure the symptoms of patients with IBS.

Methods: A self-administered 14-item symptom questionnaire (based on Rome II criteria) was mailed to 533 persons included in a prevalence study of IBS. The reliability of each underlying dimension identified was measured by Cronbach's alpha. Validity was assessed by comparing symptom scores with concurrent IBS specific quality of life (QoL) scores. Reproducibility was measured by the test-retest method and responsiveness measured by effect size.

Results: 379 (71%) questionnaires were returned. The underlying dimensions identified were pain, diarrhoea and constipation. Cronbach's alpha was 0.74 for pain, 0.90 for diarrhoea and 0.79 for constipation. Pain and diarrhoea dimensions had good external validity (r = -0.3 to -0.6), constipation dimension had moderate external validity (r = -0.2 to -0.3). All dimensions were reproducible (ICCs 0.75 to 0.81). Effect sizes of 0.27 to 0.53 were calculated for those with a reported improvement in symptoms.

Conclusion: The Birmingham IBS Symptom Questionnaire has been developed and tested. It has been shown to be suitable for self-completion and acceptable to patients. The questionnaire has 3 internal dimensions which have good reliability, external validity and are responsive to a change in health status.

References

    1. Agreus L, Svardsudd K, Nyren O, Tibblin G. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology. 1995;109:671–680. doi: 10.1016/0016-5085(95)90373-9.
    1. Thompson WG, Heaton KW. Functional bowel disorders in apparently healthy people. Gastroenterology. 1980;79:283–288.
    1. Kennedy TM, Jones RH, Hungin AP, O'Flanagan H, Kelly P. Irritable bowel syndrome, gastro-oesophageal reflux, and bronchial hyper-responsiveness in the general population. Gut. 1998;43:770–774.
    1. Drossman DA, Li Z, Andruzzi E, Temple RD, Talley NJ, Thompson WG, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci. 1993;38:1569–1580. doi: 10.1007/BF01303162.
    1. Talley NJ, Gabriel SE, Harmsen WS, Zinsmeister AR, Evans RW. Medical costs in community subjects with irritable bowel syndrome. Gastroenterology. 1995;109:1736–1741. doi: 10.1016/0016-5085(95)90738-6.
    1. Hungin AP, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther. 2003;17:643–650. doi: 10.1046/j.1365-2036.2003.01456.x.
    1. Jones R, Lydeard S. Irritable bowel syndrome in the general population. BMJ. 1992;304:87–90.
    1. Thompson WG, Heaton KW, Smyth GT, Smyth C. Irritable bowel syndrome in general practice: prevalence, characteristics, and referral. Gut. 2000;46:78–82. doi: 10.1136/gut.46.1.78.
    1. Akehurst R, Kaltenthaler E. Treatment of irritable bowel syndrome: a review of randomised controlled trials. Gut. 2001;48:272–282. doi: 10.1136/gut.48.2.272.
    1. Brandt LJ, Bjorkman D, Fennerty MB, Locke GR, Olden K, Peterson W, et al. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol. 2002;97:S7–26.
    1. Tack J, Fried M, Houghton LA, Spicak J, Fisher G. Systematic review: The efficacy of treatments for irritable bowel syndrome – A European perspective. Alimentary Pharmacology and Therapeutics. 2006;24:183–205. doi: 10.1111/j.1365-2036.2006.02938.x.
    1. Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med. 2000;133:136–147.
    1. Bensoussan A, Talley NJ, Hing M, Menzies R, Guo A, Ngu M. Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial. JAMA. 1998;280:1585–1589. doi: 10.1001/jama.280.18.1585.
    1. Cook IJ, Irvine EJ, Campbell D, Shannon S, Reddy SN, Collins SM. Effect of dietary fiber on symptoms and rectosigmoid motility in patients with irritable bowel syndrome. A controlled, crossover study. Gastroenterology. 1990;98:66–72.
    1. Klein KB. Controlled treatment trials in the irritable bowel syndrome: a critique. Gastroenterology. 1988;95:232–241.
    1. Veldhuyzen van Zanten SJ, Talley NJ, Bytzer P, Klein KB, Whorwell PJ, Zinsmeister AR. Design of treatment trials for functional gastrointestinal disorders. Gut. 1999;45:II69–77.
    1. Talley N, Nyren O, Drossman DA. The irritable bowel syndrome: toward optimal design of controlled treatment trials. Gastroenterol Int. 1993;6:189–211.
    1. Drossman DA, Corazziari E, Delvaux M, Spiller RC, Talley NJ, Thompson WG, et al. Rome III The functional gastrointestinal disorders. 3. Virginia, USA: Degnon Associates; 2006.
    1. Camilleri M, Mayer EA, Drossman DA, Heath A, Dukes GE, McSorley D, et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther. 1999;13:1149–1159. doi: 10.1046/j.1365-2036.1999.00610.x.
    1. Mangel AW, Hahn BA, Heath AT, Northcutt AR, Kong S, Dukes GE, et al. Adequate relief as an endpoint in clinical trials in irritable bowel syndrome. J Int Med Res. 1998;26:76–81.
    1. Jones RH, Holtmann G, Rodrigo L, Ehsanullah RS, Crompton PM, Jacques LA, et al. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Aliment Pharmacol Ther. 1999;13:1419–1427. doi: 10.1046/j.1365-2036.1999.00678.x.
    1. Bijkerk CJ, de Wit NJ, Muris JW, Jones RH, Knottnerus JA, Hoes AW. Outcome measures in irritable bowel syndrome: comparison of psychometric and methodological characteristics. Am J Gastroenterol. 2003;98:122–127. doi: 10.1111/j.1572-0241.2003.07158.x.
    1. Camilleri M, Mangel AW, Fehnel SE, Drossman DA, Mayer EA, Talley NJ. Primary Endpoints for Irritable Bowel Syndrome Trials: A Review of Performance of Endpoints. Clinical Gastroenterology and Hepatology. 2007;5:534–540. doi: 10.1016/j.cgh.2007.03.004.
    1. Wiklund IK, Fullerton S, Hawkey CJ, Jones RH, Longstreth GF, Mayer EA, et al. An irritable bowel syndrome-specific symptom questionnaire: development and validation. Scand J Gastroenterol. 2003;38:947–954. doi: 10.1080/00365520310004209.
    1. Bengtsson M, Ohlsson B, Ulander K. Development and psychometric testing of the Visual Analogue Scale for Irritable Bowel Syndrome (VAS-IBS) BMC Gastroenterol. 2007;7:16. doi: 10.1186/1471-230X-7-16.
    1. Patrick DL, Drossman DA, Frederick IO, DiCesare J, Puder KL. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci. 1998;43:400–411. doi: 10.1023/A:1018831127942.
    1. Drossman DA, Patrick DL, Whitehead WE, Toner BB, Diamant NE, Hu Y, et al. Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am J Gastroenterol. 2000;95:999–1007. doi: 10.1111/j.1572-0241.2000.01941.x.
    1. Wilson S, Roberts LM, Roalfe A, Bridge P, Singh S. Prevalence of irritable bowel syndrome: a community survey. British Journal of General Practice. 2004;54:495–502.
    1. Drossman D, Corazziari E, Talley N, Thompson W, Whitehead W. Rome II: The Functional Gastrointestinal Disorders: diagnosis, pathophysiology and treatment: a multinational consensus. 2. McLean VA USA: Degnon Associates; 2002.
    1. Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997;11:395–402. doi: 10.1046/j.1365-2036.1997.142318000.x.
    1. Drossman DA, Li Z, Toner BB, Diamant NE, Creed FH, Thompson D, et al. Functional bowel disorders. A multicenter comparison of health status and development of illness severity index. Dig Dis Sci. 1995;40:986–995. doi: 10.1007/BF02064187.
    1. Fitzpatrick R, Davey C, Buxton MJ, Jones DR. Evaluating patient-based outcome measures for use in clinical trials. Health Technol Assess. 1998;2
    1. Remington M, Tyrer PJ, Newson-Smith J, Cicchetti DV. Comparative reliability of categorical and analogue rating scales in the assessment of psychiatric symptomatology. Psychol Med. 1979;9:765–770.
    1. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika. 1951;16:297–334. doi: 10.1007/BF02310555.
    1. Kirshner B, Guyatt G. A methodological framework for assessing health indices. J Chronic Dis. 1985;38:27–36. doi: 10.1016/0021-9681(85)90005-0.
    1. Cohen J. Statistical Power Analysis for the Behavioural Sciences. New Jersey: LEA; 1988.
    1. Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care. 1989;27:S178–S189. doi: 10.1097/00005650-198903001-00015.
    1. Herz MJ, Kahan E, Zalevski S, Aframian R, Kuznitz D, Reichman S. Constipation:a different entity for patients and doctors. Family Practice. 1996;13:156–159. doi: 10.1093/fampra/13.2.156.
    1. Helmstadter GC. Principles of psychological measurement. New York: Appleton-Century-Crofts; 1964.
    1. Streiner DL, Norman GR. Health measurement scales: a practical guide to their development and use. 2. Oxford: Oxford University Press; 1995.
    1. Roberts L, Wilson S, Singh S, Roalfe A, Greenfield S. Gut-directed hypnotherapy for irritable bowel syndrome: piloting a primary care-based randomised controlled trial. Br J Gen Pract. 2006;56:115–121.
    1. Paterson C. Measuring outcomes in primary care: a patient generated measure, MYMOP, compared with the SF-36 health survey. BMJ. 1996;312:1016–1020.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel